Journal of materials chemistry. B
Cure8 research brief
Why This Matters
This preclinical study reports a novel oral nanoparticle that reduced inflammation and improved colon health in a mouse model of acute ulcerative colitis, pointing to a potential new delivery approach for colonic-targeted therapies.
Who Should Pay Attention
Researchers, translational scientists, and clinicians focused on drug delivery and preclinical IBD therapeutics.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper describes a laboratory and mouse-study report of a three-component, zein-coated nanoparticle formulation (sinapic acid + 6-stearoyl-L-ascorbic acid + geraniol) designed for oral, colon-targeted delivery in acute DSS-induced ulcerative colitis.
In cell and mouse experiments the nanoparticles showed antioxidant and anti-inflammatory activity, reduced disease activity in DSS-treated mice, preserved colon length, improved histology, and modulated several inflammatory markers (COX-2, iNOS, TNF-α, NF-κB, IL-1β) and barrier-related proteins (MUC-2, Claudin-1).
The work is preclinical: findings are from in vitro assays and an acute DSS mouse model, not human studies. The report focuses on formulation characteristics (particle size, charge, encapsulation efficiency), esterase-triggered release under colonic conditions, and therapeutic effects in the animal model.
This is early-stage research suggesting a possible nanotherapeutic strategy for ulcerative colitis, but it does not provide evidence about safety or efficacy in people.
Keep In Mind
Findings are from in vitro work and an acute DSS mouse model; human safety and efficacy are not addressed.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of materials chemistry. B
AuthorsAzizul Islam, Aneesh Ali, Chandrashekhar Jori +8 more
InstitutionChemical Biology Unit, Institute of Nano Science and Technology, Sector 81, Knowledge city, Sahibzada Ajit Singh Nagar, Mohali, Punjab 140306, India. rehankhan@inst.ac.in.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 28, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Chitosan-coated and sodium phytate-crosslinked porous starch microspheres for oral delivery of celastrol in colitis therapy.
The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...
Colon-targeted EGCG delivery remodels the gut microenvironment to enhance therapeutic efficacy in ulcerative colitis.
The study introduces a colon-targeted EGCG delivery system that reduced inflammation and improved microbial and metabolic markers in a mouse model of UC, suggesting a potential new therapeutic approach worth further...
Targeted β‐Glucan‐Veiled Oral Apremilast Nanotherapy Modulates Key Dysbiosis‐Associated Gut Microbiota and Alleviates Ulcerative Colitis‐Associated Anxiety, Depression, and Neuropsychiatric Behaviors
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...